Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 9/20 | 0.43 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | PYGM | P11217 | 2/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9100648 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGASLC5A1 | |
| SCHEMBL547472 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGASLC5A1 | |
| SCHEMBL4167814 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGASLC5A1 | |
| SCHEMBL1524726 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMOGASLC5A1 | |
| SCHEMBL15104602 | 0.95 | PYGB (0.38) | PYGBPYGLPYGMOGA | |
| SCHEMBL4853031 | 0.95 | PYGB (0.38) | PYGBPYGLPYGMOGA | |
| SCHEMBL8308792 | 0.84 | PYGB (0.42) | PYGBPYGLPYGMOGA | |
| SCHEMBL28543896 | 0.84 | PYGB (0.39) | PYGBPYGLPYGM | |
| SCHEMBL27352687 | 0.84 | PYGB (0.39) | PYGBPYGLPYGM | |
| SCHEMBL15125021 | 0.79 | PYGB (0.48) | PYGBPYGLPYGMOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132689-A1 | Complexing using an ortho carboxy acetal; biodrug delivery | ROCHE MADISON INC | 2008-06-05 | — | — | US | disclosed |
| US-7348453-B2 | Labile linkage for compound delivery to a cell | MIRUS BIO CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2005026253-A2 | LABILE LINKAGE FOR COMPOUND DELIVERY TO A CELL | MIRUS BIO CORPORATION (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054604-A1 | Labile linkage for compound delivery to a cell | ROCHE MADISON INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054604-A1 | Labile linkage for compound delivery to a cell | AADAC, PAICS, FURIN | PYGB 395/4885PYGL 286/4885PYGM 666/4885 |
| US-20080132689-A1 | Complexing using an ortho carboxy acetal; biodrug delivery | CEL, PAICS, OGA | PYGB 1261/4885PYGL 781/4885PYGM 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.